These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34989782)

  • 21. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
    Butt AA; Yan P; Shaikh OS
    PLoS One; 2024; 19(6):e0298254. PubMed ID: 38843201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
    Anderson AS; Caubel P; Rusnak JM;
    N Engl J Med; 2022 Sep; 387(11):1047-1049. PubMed ID: 36069818
    [No Abstract]   [Full Text] [Related]  

  • 23. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis.
    Jiang J; Li Y; Jiang Q; Jiang Y; Qin H; Li Y
    J Infect; 2024 Aug; 89(2):106190. PubMed ID: 38834107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The global COVID-19 treatment divide.
    Usher AD
    Lancet; 2022 Feb; 399(10327):779-782. PubMed ID: 35219388
    [No Abstract]   [Full Text] [Related]  

  • 25. Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response.
    Ramchandani R; Kazatchkine M; Liu J; Sudan P; Dybul M; Matsoso P; Nordström A; Phelan A; Legido-Quigley H; Singh S; Mabuchi S
    BMJ; 2021 Nov; 375():e067488. PubMed ID: 34840135
    [No Abstract]   [Full Text] [Related]  

  • 26. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bad news for Paxlovid? Resistance may be coming.
    Service RF
    Science; 2022 Jul; 377(6602):138-139. PubMed ID: 35857562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19: LMICs need antivirals as well as vaccines.
    Bajaj SS; Stanford FC
    Nature; 2022 Feb; 602(7895):33. PubMed ID: 35105995
    [No Abstract]   [Full Text] [Related]  

  • 29. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.
    Heskin J; Pallett SJC; Mughal N; Davies GW; Moore LSP; Rayment M; Jones R
    Lancet; 2022 Jan; 399(10319):21-22. PubMed ID: 34973713
    [No Abstract]   [Full Text] [Related]  

  • 30. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
    Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
    Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Audio Interview: A Potential New Agent to Treat Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(26):e101. PubMed ID: 34936745
    [No Abstract]   [Full Text] [Related]  

  • 32. Molnupiravir for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):10-11. PubMed ID: 35134041
    [No Abstract]   [Full Text] [Related]  

  • 33. [Molnupiravir reduces symptoms duration but does not decrease hospitalizations or deaths in vaccinated adults with Covid-19.].
    Kurotschka PK; Ebell MH; Serafini A
    Recenti Prog Med; 2024 Sep; 115(9):400-401. PubMed ID: 39269353
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.
    Denning K; Sheppard J; Carico R
    J Am Pharm Assoc (2003); 2024; 64(2):530-534. PubMed ID: 38151202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An oral SARS-CoV-2 M
    Owen DR; Allerton CMN; Anderson AS; Aschenbrenner L; Avery M; Berritt S; Boras B; Cardin RD; Carlo A; Coffman KJ; Dantonio A; Di L; Eng H; Ferre R; Gajiwala KS; Gibson SA; Greasley SE; Hurst BL; Kadar EP; Kalgutkar AS; Lee JC; Lee J; Liu W; Mason SW; Noell S; Novak JJ; Obach RS; Ogilvie K; Patel NC; Pettersson M; Rai DK; Reese MR; Sammons MF; Sathish JG; Singh RSP; Steppan CM; Stewart AE; Tuttle JB; Updyke L; Verhoest PR; Wei L; Yang Q; Zhu Y
    Science; 2021 Dec; 374(6575):1586-1593. PubMed ID: 34726479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia.
    Yii YC; Shih HM; Chen CL; Lai ZL; Hsu YL; Lai CH; Hsueh PR; Cho DY
    Int J Antimicrob Agents; 2024 Jan; 63(1):107020. PubMed ID: 37898365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed treatment with nirmatrelvir/ritonavir could remain effective in patients with Omicron BA2.2 variant of COVID-19.
    Wang W; Wan J; Du W; Song J; Lu Y; Gu S; Feng Y; Wang G; Tao M; Yin J
    Ann Acad Med Singap; 2023 Mar; 52(3):158-160. PubMed ID: 38904494
    [No Abstract]   [Full Text] [Related]  

  • 38. Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination.
    Kadire SR; Wachter RM; Lurie N
    N Engl J Med; 2021 Mar; 384(9):e28. PubMed ID: 33596347
    [No Abstract]   [Full Text] [Related]  

  • 39. Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare.
    Kuehn BM
    JAMA; 2022 Jul; 328(4):323. PubMed ID: 35881113
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety and efficacy of antivirals against SARS-CoV-2.
    Sidebottom DB; Smith DD; Gill D
    BMJ; 2021 Oct; 375():n2611. PubMed ID: 34711614
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.